Age-related macular degeneration therapy: a review
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose of review: The purpose of this review is to describe the current clinical landscape of potential future therapies for both nonexudative (dry) and exudative (wet) age-related macular degeneration (AMD). We highlight some of the more promising treatments that are furthest along in development. Recent findings: Patients with dry AMD have long been hoping for a highly efficacious treatment that may slow disease progression or even help regain vision. Patients with wet AMD have many effective treatment options but still there are those who have suboptimal responses or are burdened by the high frequency of treatment. We detail exciting new concepts and targets for novel medications. Specifically, for dry AMD we discuss research looking at complement inhibition, neuroprotection, visual cycle modulators, cell-based therapies, and anti-inflammatory agents. For wet AMD we summarize new, potentially more durable anti-vascular endothelial growth factor agents, extended release options, and gene therapy. Summary: There are promising new strategies for AMD. Many of the potential new treatments are in or have recently completed phase 2 or phase 3 clinical trials with promising results thus far, including some that have received US Food and Drug Administration approval. Additional therapeutic breakthroughs will likely continue to occur thanks to the number of clinical trials that are nearing the finish line.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327 · cited 1×
“Optical coherence tomography (OCT) showed reconstitution or thickening of the RPE layer in some subjects [20].”
BackgroundSelf-citationDugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
HTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
DeWan, A., Liu, M., Hartman, S., Zhang, S. S.-M., Liu, D. T. L., Zhao, C., Tam, P. O. S., Chan, W. M., Lam, D. S. C., Snyder, M., et al. (2006) · Science · doi:10.1126/science.1133807 · Cited by 876 · cited 1×
“Recent studies have shown HTRA1 to be a major risk factor for wet AMD [31].”
BackgroundAnderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727
Dugel, P. U., Jaffe, G. J., Sallstig, P., Warburton, J., Weichselberger, A., Wieland, M., & Singerman, L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.03.057 · Cited by 236
Cited by
Age-related macular degeneration
Fleckenstein, M., Keenan, T. D. L., Guymer, R. H., Chakravarthy, U., Schmitz-Valckenberg, S., Klaver, C. C., Wong, W. T., & Chew, E. Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00265-2 · Cited by 978
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., & Hatley, R. J. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 540
Simultaneous perception of prosthetic and natural vision in AMD patients
Palanker, D., Le Mer, Y., Mohand-Said, S., & Sahel, J. A. (2022) · Nature Communications · doi:10.1038/s41467-022-28125-x · Cited by 140
Sghaier, R., Perus, M., Cornebise, C., Courtaut, F., Scagliarini, A., Olmiere, C., Aires, V., Hermetet, F., & Delmas, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911704 · Cited by 11
Intravitreal CendR peptides target laser-induced choroidal neovascularization sites in mice
Puranen, J., Korhonen, S., Haugas, M., Lingasamy, P., Teesalu, T., Subrizi, A., Urtti, A., Ruponen, M., & Reinisalo, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.025 · Cited by 10
Metadata
- Authors
- Ammar, M. J., Hsu, J., Chiang, A., Ho, A. C., & Regillo, C. D.
- Venue
- Current Opinion in Ophthalmology
- Published
- 2020-05
- Volume
- 31
- Issue
- 3
- Pages
- 215-221
- ISSN
- 1040-8738 (ISSN-L)
- 1531-7021
- OpenAlex
- W3012834768
- Cited by
- 136
- References
- 5
- FWCI
- 15.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Age-related macular degeneration therapy: a review. https://app.cochat.ai/papers/10.1097/icu.0000000000000657
- The paper
- Ammar, M. J., Hsu, J., Chiang, A., Ho, A. C., & Regillo, C. D. (2020). Age-related macular degeneration therapy: a review. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0000000000000657
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.